Sanofi wins $226m in funds to expand influenza vaccine capacity in US
Category: #headlines  By Saipriya Iyer  Date: 2019-12-10
  • share
  • Twitter
  • Facebook
  • LinkedIn
Sanofi wins $226m in funds to expand influenza vaccine capacity in US
  • The agreement is supported by federal funds from BARDA
     
  • A new manufacturing unit is to be established to facilitate sustainable production

France based pharmaceutical company- Sanofi Pasteur has reportedly signed an agreement with the U.S. Department of Health and Human Services to increase the production capacity of company’s domestic pandemic influenza vaccines in Swiftwater, Pennsylvania.

The agreement is supported by federal funds received from the Biomedical Advance Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at HHS.

According to David Loew, Executive Vice President of Vaccines at Sanofi, the contract will allow the company to enhance the supply of flu vaccines under cases of pandemic influenza. Sanofi Pasteur is focusing on advancing influenza vaccine technology along with enhancing the manufacturing mechanism, the public-private partnership will furthermore help safeguard people from influenza, he added.

Apparently, the agreement will foster clinical development and manufacturing of a recombinant pandemic vaccine to prepare the world for a global pandemic situation. The investigational pandemic vaccine will use the same technology as that of Flublok® Quadrivalent – an influenza vaccine developed by Sanofi.  

Moreover, the contract will enlarge the company’s role as a leading solution for pandemic preparedness by adding both adjuvant and recombinant manufacturing along with the prevailing egg-based manufacturing technique.

For the record, Flublok Quadrivalent may be given to adults above the age of 18 and is proven to prevent more than 30% to 43% confirmed cases of the infection in people who are 50 years old and above, as compared to its alternate vaccine.

Flublok Quadrivalent is the sole and effective protein-based influenza treatment solution which is approved by the U.S. Food and Drug Administration (FDA), rendering a precise genetic match of hemagglutinin (HA) from each suggested vaccine virus. HA is primarily a protein that is key to stimulating immunity to influenza.  

Sanofi is a global biopharmaceutical firm that primarily focuses on providing support to people through their health challenges. The company aims at preventing illness with the help of vaccines, providing advanced treatment techniques to fight pain and reduce suffering.

 

Source Credits: http://www.news.sanofi.us/2019-12-09-Sanofi-awarded-226-million-by-US-government-to-expand-pandemic-influenza-preparedness

  • share
  • Twitter
  • Facebook
  • LinkedIn

About Author

Saipriya Iyer

Saipriya Iyer    

Saipriya Iyer currently works as a content developer for GroundAlerts. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had previous experience of 3 years under her belt, she has dabbled with website ...

Read More >>

More News By Saipriya Iyer

Global Wooden Furniture Market by Key Players, Countries, Segments and Application, Forecast to 2027
Global Wooden Furniture Market by Key Players, Countries, Segments and Application, Forecast to 2027
By Saipriya Iyer

Global wooden furniture market is poised to witness a tremendous growth over the projected timeframe of 2020 to 2026 on account of rising number of residential and commercial construction activities across the globe. Alongside, increasing consumer in...

Cladribine Market Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast To 2026
Cladribine Market Growth Manufacturers, Regions, Product Types, Major Application Analysis & Forecast To 2026
By Saipriya Iyer

Global Cladribine Market Research Report: Size, Share, Trends, Industry Growth, Opportunity, Application, Production, Segmentation, Cost Structure, Company Profile, Product Picture and Specifications during the Forecast period by 2026 Executive summ...

Cardiovascular Disease Drugs Market size and Key Trends in terms of volume and value 2021-2026
Cardiovascular Disease Drugs Market size and Key Trends in terms of volume and value 2021-2026
By Saipriya Iyer

Global Cardiovascular Disease Drugs ?Market report 2026 focuses on the major Types and Applications for the key players. Global Cardiovascular Disease Drugs market research report also provides analysis of the market share, segmentation, revenue fore...